The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma

The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma

Saved in:

Bibliographic Details
Main Authors:	L. Mortier, N. Meyer, J.-J. Grob, M. Pouriel, D. de Carpentier, P. Saïag
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001770
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
by: Takuji Seo, et al.
Published: (2020-01-01)

A post-marketing surveillance study of dabrafenib and trametinib combination in Japanese patients with unresectable advanced or recurrent BRAF-mutated NSCLC
by: Tomoaki Kaizuka, et al.
Published: (2025-07-01)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021-01-01)

Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice
by: Alexandra Savova, et al.
Published: (2024-12-01)

The combination of dabrafenib/trametinib is approved for the treatment of pediatric glioma
by: article Editorial
Published: (2023-05-01)

Dabrafenib and trametinib either in combination or as monotherapy in pediatric patients harboring BRAF alterations in gliomas or other rare tumors: Findings from a managed access program
by: Mark Russo, et al.
Published: (2025-06-01)

Enhanced response to dabrafenib plus trametinib in a patient with BRAFV600E lung cancer harboring an RNF43 variant of unknown significance: a case report
by: Ettore D’Argento, et al.
Published: (2025-07-01)

The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis
by: Mohammad Amin Habibi, et al.
Published: (2025-06-01)

Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis
by: Bardia Hajikarimloo, et al.
Published: (2024-11-01)

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
by: Monika Joshi, et al.
Published: (2015-01-01)

An 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib – a case report and literature review
by: Sue Lyn Tan, et al.
Published: (2025-03-01)

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024-02-01)

Romeo & Juliet /
by: Shakespeare, William, 1564-1616
Published: (2008)

Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers
by: Pawel Sadlecki, et al.
Published: (2017-05-01)

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia
by: N. A. Avxentyev, et al.
Published: (2023-11-01)

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
by: J. Ros, et al.
Published: (2025-09-01)

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-03-01)

Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review
by: Shingo FUJIO, et al.
Published: (2025-05-01)

Correction: Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-04-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)

Tito Menzani, "Romeo Galaverni"
by: Matteo Troilo
Published: (2021-12-01)

Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma
by: Bernies van der Hiel, et al.
Published: (2025-05-01)

Axillary cutaneous metastasis of colon cancer with microsatellite instability-high and BRAF V600E mutation treated with curative-intent surgery: a case report
by: Daisuke Yamai, et al.
Published: (2023-11-01)

Capacity analysis of the MEO satellite constellation
by: Ya-hui WANG, et al.
Published: (2017-10-01)

Transsulfuration Reprogramming: A Metabolic Driver of BRAF‐V600E Resistance in Melanoma
by: Juntong Chen, et al.
Published: (2025-06-01)

Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
by: Bethy S Hernowo, et al.
Published: (2016-05-01)

Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
by: Bethy S Hernowo, et al.
Published: (2016-05-01)

Patient treatment preferences in unresectable/metastatic BRAF-mutated melanoma: a qualitative study
by: T. Amaral, et al.
Published: (2024-01-01)

THE ROLE OF BRAF V600E IN THE DEVELOPMENT OF THYROID CANCER PHENOTYPE: A SYSTEMATIC REVIEW
by: Pratia Mega, et al.
Published: (2025-01-01)

A multi-center cross-sectional investigation of BRAF V600E mutation in Ameloblastoma
by: Khin Mya Tun, et al.
Published: (2025-04-01)

Frequent mutation of K-RAS in addition to BRAF V600E in Ameloblastoma – An immunohistochemical study
by: Aishwariya Mohanty, et al.
Published: (2024-06-01)

BRAF V600E Mutation in Odontogenic Keratocyst: A Systematic Review and Meta-Analysis
by: Jéssica da Silva Cunha, et al.
Published: (2025-01-01)

BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
by: Jennifer A. Silver, et al.
Published: (2021-11-01)

Polychrome sculptures in Romeo and Juliet and The Winter’s Tale
by: Olivia COULOMB
Published: (2015-06-01)

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis.
by: David S Nelson, et al.
Published: (2019-01-01)

Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry.
by: Ana Claudia Urvanegia, et al.
Published: (2017-01-01)

Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature
by: Hirra A. Chaudhary, et al.
Published: (2024-08-01)

Analysis on the coverage performance and networking scheme of an MEO constellation
by: Yanbin ZHAO, et al.
Published: (2022-04-01)